1-cyclohexyl-3-[(3S)-3,5-dichloro-2-cyclohexyl-6-(3,5-dichlorophenoxy)-2H-furo[3,2-b]furan-3-yl]urea

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyclohexyl-3-[(3S)-3,5-dichloro-2-cyclohexyl-6-(3,5-dichlorophenoxy)-2H-furo[3,2-b]furan-3-yl]urea
• 化学式: C₂₅H₂₈Cl₄N₂O₄
• 分子量: 562.3
• InChiKey: MIUAHPVSWLHPPI-UIDYPRJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  72.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE
  申请人：SANOFI

  公开号：EP2945950A1

  公开（公告）日：2015-11-25
• [EN] ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE<br/>[FR] DÉRIVÉS D'ISOMANNIDE UTILISÉS COMME INHIBITEURS D'ÉPOXYDE HYDROLASE SOLUBLE
  申请人：SANOFI SA

  公开号：WO2014111465A1

  公开（公告）日：2014-07-24

  The present invention relates to compounds of the formula (I), wherein R1, R11, R12 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, inflammation or could show beneficial effects in pain, dyslipidemia and atherosclerosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.